- Home
- INCY vs EXAS Comparison
INCY vs EXAS Comparison
Compare INCY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- EXAS
- Stock Information
- Founded
- INCY 1991
- EXAS 1995
- Country
- INCY United States
- EXAS United States
- Employees
- INCY N/A
- EXAS N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- EXAS Medical Specialities
- Sector
- INCY Health Care
- EXAS Health Care
- Exchange
- INCY Nasdaq
- EXAS Nasdaq
- Market Cap
- INCY 13.4B
- EXAS 10.7B
- IPO Year
- INCY 1993
- EXAS N/A
- Fundamental
- Price
- INCY $68.46
- EXAS $53.02
- Analyst Decision
- INCY Hold
- EXAS Strong Buy
- Analyst Count
- INCY 20
- EXAS 20
- Target Price
- INCY $73.81
- EXAS $70.68
- AVG Volume (30 Days)
- INCY 2.0M
- EXAS 2.9M
- Earning Date
- INCY 07-29-2025
- EXAS 07-30-2025
- Dividend Yield
- INCY N/A
- EXAS N/A
- EPS Growth
- INCY N/A
- EXAS N/A
- EPS
- INCY 0.10
- EXAS N/A
- Revenue
- INCY $4,413,226,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- INCY $13.29
- EXAS $14.58
- Revenue Next Year
- INCY $10.47
- EXAS $12.75
- P/E Ratio
- INCY $705.59
- EXAS N/A
- Revenue Growth
- INCY 17.13
- EXAS 11.57
- 52 Week Low
- INCY $53.56
- EXAS $39.97
- 52 Week High
- INCY $83.95
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- INCY 56.95
- EXAS 45.95
- Support Level
- INCY $67.57
- EXAS $51.50
- Resistance Level
- INCY $71.29
- EXAS $53.30
- Average True Range (ATR)
- INCY 1.98
- EXAS 1.62
- MACD
- INCY -0.13
- EXAS -0.64
- Stochastic Oscillator
- INCY 61.55
- EXAS 26.95
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.